Snider Financial Group Grows Position in Stryker Corporation $SYK

Snider Financial Group lifted its position in shares of Stryker Corporation (NYSE:SYK) by 1.9% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,206 shares of the medical technology company’s stock after purchasing an additional 222 shares during the quarter. Stryker comprises 1.4% of Snider Financial Group’s investment portfolio, making the stock its 21st biggest holding. Snider Financial Group’s holdings in Stryker were worth $4,829,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in SYK. Mar Vista Investment Partners LLC raised its stake in Stryker by 10.2% during the 1st quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company’s stock worth $33,572,000 after acquiring an additional 8,353 shares during the period. United Services Automobile Association purchased a new stake in shares of Stryker in the first quarter worth $2,857,000. AXS Investments LLC increased its stake in shares of Stryker by 13.7% in the first quarter. AXS Investments LLC now owns 8,827 shares of the medical technology company’s stock worth $3,286,000 after purchasing an additional 1,062 shares in the last quarter. Park Edge Advisors LLC bought a new stake in shares of Stryker during the 2nd quarter valued at $679,000. Finally, Motco lifted its stake in shares of Stryker by 3,157.8% during the 2nd quarter. Motco now owns 23,228 shares of the medical technology company’s stock valued at $9,122,000 after buying an additional 22,515 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the sale, the director directly owned 3,222,108 shares in the company, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Viju Menon sold 500 shares of the company’s stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 5.90% of the company’s stock.

Stryker Price Performance

Shares of Stryker stock opened at $356.15 on Monday. The firm has a market cap of $136.16 billion, a PE ratio of 47.17, a PEG ratio of 2.66 and a beta of 0.94. The stock has a 50 day moving average of $378.08 and a 200 day moving average of $381.04. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. The business had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, research analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Tuesday, September 30th were paid a dividend of $0.84 per share. The ex-dividend date of this dividend was Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. Stryker’s dividend payout ratio is presently 44.15%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on SYK shares. BTIG Research raised their price target on Stryker from $408.00 to $410.00 and gave the company a “buy” rating in a report on Friday. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, October 18th. Rothschild Redb raised Stryker to a “hold” rating in a research note on Thursday, September 18th. Needham & Company LLC boosted their price target on Stryker from $442.00 to $448.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Finally, Rothschild & Co Redburn assumed coverage on Stryker in a research note on Thursday, September 18th. They issued a “neutral” rating and a $420.00 price target for the company. Thirteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $434.16.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.